Skip to main content
Nathan Steinle, MD, Ophthalmology, Santa Barbara, CA

Nathan Christopher Steinle MD

Retinal Disease


Physician

Join to View Full Profile
  • 525 E Micheltorena StSte ASanta Barbara, CA 93103

  • Phone+1 805-963-1648

  • Fax+1 805-965-5214

Dr. Steinle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Surgical Retina and Vitreous, 2009 - 2011
  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineResidency, Ophthalmology, 2006 - 2009
  • University of Kentucky College of Medicine (Bowling Green)
    University of Kentucky College of Medicine (Bowling Green)Internship, Transitional Year, 2005 - 2006
  • University of South Dakota, Sanford School of Medicine
    University of South Dakota, Sanford School of MedicineClass of 2005

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2011 - 2027
  • SD State Medical License
    SD State Medical License Active through 2027
  • WY State Medical License
    WY State Medical License 2021 - 2025
  • KY State Medical License
    KY State Medical License 2020 - 2022
  • OH State Medical License
    OH State Medical License 2009 - 2012
  • Ophthalmology
    American Board of Ophthalmology Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Research Promises Better Diabetic Retinopathy Management
    Research Promises Better Diabetic Retinopathy ManagementAugust 16th, 2024
  • July 29, 2018
    July 29, 2018July 29th, 2018
  • SYFOVRE® (Pegcetacoplan Injection) Continued to Demonstrate Increasing Treatment Effects over 30 Months in Patients with Geographic Atrophy (GA)
    SYFOVRE® (Pegcetacoplan Injection) Continued to Demonstrate Increasing Treatment Effects over 30 Months in Patients with Geographic Atrophy (GA)July 31st, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: